MedTrace Logo

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

NCT01082588 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-04-28

Study results available
· View outcomes & findings →

Summary

This study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. Some antipsychotic medications may cause an increase in cholesterol levels, which may lead to inflammation in the body. Inflammation poses a risk in developing heart disease, diabetes and problems with brain function. The purpose of this study is to see if pravastatin can:

* Lower cholesterol
* Decrease inflammation
* Improve cognition in patients with schizophrenia

Conditions

  • Schizophrenia
  • Schizoaffective Disorders
  • Schizophreniform Disorders

Interventions

DRUG

Pravastatin

pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks

DRUG

Placebo

pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • North Suffolk Mental Health Association

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • David C Henderson, M.D. · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01082588 on ClinicalTrials.gov